• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Surrozen Inc.

    4/19/24 4:34:41 PM ET
    $SRZN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $SRZN alert in real time by email
    SC 13G 1 surrozen13g.htm

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    SCHEDULE 13G

    Under the Securities Exchange Act of 1934
    (Amendment No. ___)*

     

     

    Surrozen, Inc.

    (Name of Issuer)

     

     

    Common Stock, $0.0001 par value per share

    (Title of Class of Securities)

     

     

    86889P208

    (CUSIP Number)

     

     

    April 1, 2024

    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    [X]       Rule 13d-1(b)

     

    [X]       Rule 13d-1(c)

     

    [ ]       Rule 13d-1(d)

     

    * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

    Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

     

     1 

    CUSIP No. 86889P208

     

    1.Names of Reporting Persons.

    Stonepine Capital Management, LLC

     

    2.Check the Appropriate Box if a Member of a Group (See Instructions)

    (a) ______

    (b) X

     

    3. SEC Use Only

     

    4.Citizenship or Place of Organization Delaware

     

    Number of

    Shares

    Beneficially

    Owned by

    Each Reporting

    Person With:

    5. Sole Voting Power 0

     

    6. Shared Voting Power 199,158

     

    7. Sole Dispositive Power 0
    8. Shared Dispositive Power 199,158

     

    9.Aggregate Amount Beneficially Owned by Each Reporting Person 199,158

     

    10.Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See
    Instructions) ______

     

    11.Percent of Class Represented by Amount in Row (9) 6.0%

     

    12.Type of Reporting Person (See Instructions) IA, OO

     

     2 

    CUSIP No. 86889P208

     

    1.Names of Reporting Persons.

    Stonepine Capital, L.P.

     

    2.Check the Appropriate Box if a Member of a Group (See Instructions)

    (a) ______

    (b) X

     

    3. SEC Use Only

     

    4.Citizenship or Place of Organization Delaware

     

    Number of

    Shares

    Beneficially

    Owned by

    Each Reporting

    Person With:

    5. Sole Voting Power 0

     

    6. Shared Voting Power 199,158

     

    7. Sole Dispositive Power 0
    8. Shared Dispositive Power 199,158

     

    9.Aggregate Amount Beneficially Owned by Each Reporting Person 199,158

     

    10.Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See
    Instructions) ______

     

    11.Percent of Class Represented by Amount in Row (9) 6.0%

     

    12.Type of Reporting Person (See Instructions) PN

     

     3 

    CUSIP No. 86889P208

    1.Names of Reporting Persons.

    Stonepine GP, LLC

     

    2.Check the Appropriate Box if a Member of a Group (See Instructions)

    (a) ______

    (b) X

     

    3. SEC Use Only

     

    4.Citizenship or Place of Organization Delaware

     

    Number of

    Shares

    Beneficially

    Owned by

    Each Reporting

    Person With:

    5. Sole Voting Power 0

     

    6. Shared Voting Power 199,158

     

    7. Sole Dispositive Power 0
    8. Shared Dispositive Power 199,158

     

    9.Aggregate Amount Beneficially Owned by Each Reporting Person 199,158

     

    10.Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See
    Instructions) ______

     

    11.Percent of Class Represented by Amount in Row (9) 6.0%

     

    12.Type of Reporting Person (See Instructions) OO

     

     4 

    CUSIP No. 86889P208

     

    1.Names of Reporting Persons.

    Jon M. Plexico

     

    2.Check the Appropriate Box if a Member of a Group (See Instructions)

    (a) ______

    (b) X

     

    3. SEC Use Only

     

    4.Citizenship or Place of Organization U.S.A.

     

    Number of

    Shares

    Beneficially

    Owned by

    Each Reporting

    Person With:

    5. Sole Voting Power 0

     

    6. Shared Voting Power 199,158

     

    7. Sole Dispositive Power 0
    8. Shared Dispositive Power 199,158

     

    9.Aggregate Amount Beneficially Owned by Each Reporting Person 199,158

     

    10.Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See
    Instructions) ______

     

    11.Percent of Class Represented by Amount in Row (9) 6.0%

     

    12.Type of Reporting Person (See Instructions) HC, IN

     

     5 

    CUSIP No. 86889P208

    1.Names of Reporting Persons.

    Timothy P. Lynch

     

    2.Check the Appropriate Box if a Member of a Group (See Instructions)

    (a) ______

    (b) X

     

    3. SEC Use Only

     

    4.Citizenship or Place of Organization U.S.A.

     

    Number of

    Shares

    Beneficially

    Owned by

    Each Reporting

    Person With:

    5. Sole Voting Power 0

     

    6. Shared Voting Power 199,158

     

    7. Sole Dispositive Power 0
    8. Shared Dispositive Power 199,158

     

    9.Aggregate Amount Beneficially Owned by Each Reporting Person 199,158

     

     

    10.Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See
    Instructions) ______

     

    11.Percent of Class Represented by Amount in Row (9) 6.0%

     

    12.Type of Reporting Person (See Instructions) HC, IN

     

     6 

    CUSIP No. 86889P208

    Item 1.

     

    (a)Name of Issuer

    Surrozen, Inc.

     

    (b)Address of Issuer’s Principal Executive Offices

    171 Oyster Point Blvd., Suite 400, South San Francisco, CA 94080

     

     

    Item 2.

     

    (a)The names of the persons filing this statement are:


    Stonepine Capital Management, LLC, a Delaware limited liability company (“Stonepine”)

     

    Stonepine Capital, L.P., a Delaware limited partnership (the “Partnership”)

     

    Stonepine GP, LLC, a Delaware limited liability company (the “General Partner”)

     

    Jon M. Plexico

     

    Timothy P. Lynch (collectively, the “Filers”)

     

    Stonepine and the General Partner are the investment adviser and general partner, respectively, of investment funds, including the Partnership. Mr. Plexico and Mr. Lynch are the control persons of Stonepine and the General Partner. The Filers are filing this Schedule 13G jointly, but not as members of a group, and each disclaims membership in a group. Each Filer also disclaims beneficial ownership of the Stock except to the extent of that person’s pecuniary interest therein. In addition, the filing of this Schedule 13G on behalf of the Partnership should not be construed as an admission that it is, and it disclaims that it is, a beneficial owner, as defined in Rule 13d-3 under the Act, of any of the Stock covered by this Schedule 13G.

     

    (b)The principal business office of the Filers is located at

     

    919 NW Bond Street, Suite 204

    Bend, OR 97703

     

    (c)For citizenship of Filers, see Item 4 of the cover sheet for each Filer.

     

    (d)This statement relates to the Issuer’s Common Stock, $0.0001 par value per share (the “Stock”).

     

    (e)The CUSIP number of the Issuer is: 86889P208
     7 

    CUSIP No. 86889P208

    Item 3.If this statement is filed pursuant to rule 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

     

    (a)[ ] Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).

     

    (b)[ ] Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).

     

    (c)[ ] Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).

     

    (d)[ ] Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).

     

    (e)[X] An investment adviser in accordance with section 240.13d-1(b)(1)(ii)(E). As to Stonepine and the General Partner.

     

    (f)[ ] An employee benefit plan or endowment fund in accordance with section 240.13d-1(b)(1)(ii)(F).

     

    (g)[X] A parent holding company or control person in accordance with 240.13d-1(b)(1)(ii)(G). As to Mr. Plexico and Mr. Lynch.

     

    (h)[ ] A savings association as defined in section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813).

     

    (i)[ ] A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3).

     

    (j)[ ] A non-U.S. institution in accordance with §240.13d-1(b)(ii)(J).

     

    (k)[ ] Group, in accordance with Rule 13d-1(b)(1)(ii)(K).

     

    If filing as a non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J), please specify the type of institution _______________________________________________________________.

     

    Item 4.Ownership.

     

    See Items 5-9 and 11 of the cover page for each Filer.

     

    The shares of Common Stock beneficially owned by the Filers reported in this Schedule 13G consist of (1) 64,500 shares of Common Stock, (2) 64,500 shares of Common Stock issuable on exercise of Series A Warrants, and (3) 70,158 shares of Common Stock issuable on exercise of Series B Warrants. This Schedule 13G does not include 499,874 shares issuable on exercise of Series C Warrants and Series D Warrants, which are not exercisable within 60 days. The Series A Warrants, Series B Warrants, Series C Warrants and Series D Warrants are each subject to a 9.99% beneficial ownership limitation. The percentages reported in this Schedule 13G are based on 3,198,786 shares of Common Stock outstanding as of April 8, 20204, as reported in the Form 10-K filed by the Issuer on April 10, 2024.

     

    Item 5.Ownership of Five Percent or Less of a Class

     

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following [ ].

     8 

    CUSIP No. 86889P208

     

    Item 6.Ownership of More than Five Percent on Behalf of Another Person.

     

    The Partnership holds the Stock for the benefit of its investors and has the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the Stock.

     

    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company.

     

    Not applicable.

     

    Item 8.Identification and Classification of Members of the Group.

     

    Not applicable.

     

    Item 9.Notice of Dissolution of Group

     

    Not applicable.


    Item 10.
    Material to Be Filed as Exhibits

    Agreement Regarding Joint Filing of Statement on Schedule 13D or 13G.

    Item 11.Certification of Stonepine, the General Partner, Mr. Plexico and Mr. Lynch

     

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

    Certification of the Partnership

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

     9 

    CUSIP No. 86889P208

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Dated: April 19, 2024

     

     

     

    STONEPINE CAPITAL MANAGEMENT, LLC


    By: /s/ Timothy P. Lynch
    Timothy P. Lynch
    Managing Member

     

     

    STONEPINE CAPITAL, L.P.

    By: Stonepine GP, LLC,
    General Partner

    By: /s/ Timothy P. Lynch
    Timothy P. Lynch
    Managing Member

     

     

    STONEPINE GP, LLC


    By: /s/ Timothy P. Lynch
    Timothy P. Lynch
    Managing Member

     

     

     

    /s/ Jon M. Plexico

    Jon M. Plexico

     

     

    /s/ Timothy P. Lynch

    Timothy P. Lynch

     10 

    CUSIP No. 86889P208

    EXHIBIT A

     

    AGREEMENT REGARDING JOINT FILING

    OF STATEMENT ON SCHEDULE 13D OR 13G

     

    The undersigned agree to file jointly with the Securities and Exchange Commission (the “SEC”) any and all statements on Schedule 13D or Schedule 13G or Forms 3, 4 or 5(and any amendments or supplements thereto) required under section 13(d) and 16(a) of the Securities Exchange Act of 1934, as amended, in connection with purchases by the undersigned of the securities of any issuer. For that purpose, the undersigned hereby constitute and appoint Stonepine Capital Management, LLC, a Delaware limited liability company, as their true and lawful agent and attorney-in-fact, with full power and authority for and on behalf of the undersigned to prepare or cause to be prepared, sign, file with the SEC and furnish to any other person all certificates, instruments, agreements and documents necessary to comply with section 13(d) and section 16(a) of the Securities Exchange Act of 1934, as amended, in connection with said purchases, and to do and perform every act necessary and proper to be done incident to the exercise of the foregoing power, as fully as the undersigned might or could do if personally present.

     

    Dated: April 19, 2024

     

     

    STONEPINE CAPITAL MANAGEMENT, LLC


    By: /s/ Timothy P. Lynch
    Timothy P. Lynch
    Managing Member

     

     

    STONEPINE CAPITAL, L.P.

    By: Stonepine GP, LLC,
    General Partner

    By: /s/ Timothy P. Lynch
    Timothy P. Lynch
    Managing Member

     

     

    STONEPINE GP, LLC


    By: /s/ Timothy P. Lynch
    Timothy P. Lynch
    Managing Member

     

     

     

    /s/ Jon M. Plexico

    Jon M. Plexico

     

     

    /s/ Timothy P. Lynch

    Timothy P. Lynch

     

    Get the next $SRZN alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $SRZN

    DatePrice TargetRatingAnalyst
    1/30/2025$32.00Buy
    H.C. Wainwright
    1/3/2025$45.00Neutral → Buy
    Guggenheim
    10/11/2021$11.00Buy
    B of A Securities
    9/15/2021$20.00Buy
    Guggenheim
    9/7/2021$19.00Buy
    Stifel
    More analyst ratings

    $SRZN
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Surrozen Granted Patent from U.S. Patent and Trademark Office Directed to Antibody-Based Molecules Targeting Key Receptors in the Wnt Pathway

      Newly granted patent is part of the expanding intellectual property portfolio directed to: -generating novel and selective Wnt surrogate molecules with potentially broad therapeutic utility and -incorporating novel discoveries related to requirements for efficient and selective Wnt pathway signaling SOUTH SAN FRANCISCO, Calif., May 14, 2025 (GLOBE NEWSWIRE) -- Surrozen, Inc. ("Surrozen" or the "Company") (NASDAQ:SRZN), a company pioneering targeted therapeutics that selectively activate the Wnt Pathway for tissue repair and regeneration, today announced the issuance of U.S. Patent No. 12,297,278. Surrozen has six issued U.S. patents, 10 patents issued in other countries, 11 patent fami

      5/14/25 8:30:01 AM ET
      $SRZN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Surrozen Reports First Quarter 2025 Financial Results and Provides Business Update

      SOUTH SAN FRANCISCO, Calif., May 09, 2025 (GLOBE NEWSWIRE) -- Surrozen, Inc. ("Surrozen" or the "Company") (NASDAQ:SRZN), a biotechnology company pioneering targeted therapeutics that selectively modulate the Wnt pathway for tissue repair and regeneration, with a focus on severe eye diseases, today announced financial results for the first quarter ended March 31, 2025, and provided a business update. Business Highlights Surrozen has pivoted its focus to its ophthalmology pipeline, leveraging its Wnt biology expertise and antibody technologies to develop novel treatments for severe eye diseases, including age-related macular degeneration (AMD) and diabetic retinopathy. The Company discont

      5/9/25 4:05:08 PM ET
      $SRZN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Surrozen Provides Fourth Quarter and Full Year 2024 Financial Results and Business Updates

      SOUTH SAN FRANCISCO, Calif., March 31, 2025 (GLOBE NEWSWIRE) -- Surrozen, Inc. ("Surrozen" or the "Company") (NASDAQ:SRZN), a company pioneering targeted therapeutics that selectively activate the Wnt pathway for tissue repair and regeneration, with a focus on severe eye diseases, today provided fourth quarter and full year 2024 financial results and business updates. Research and Development Pipeline Highlights The company prioritized its ophthalmology pipeline programs that have the potential to provide new or improved treatment options in multiple severe and disabling eye diseases. Surrozen will focus its Wnt biology expertise and Wnt signal modulation antibody technologies on its oph

      3/31/25 4:05:16 PM ET
      $SRZN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $SRZN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • H.C. Wainwright initiated coverage on Surrozen with a new price target

      H.C. Wainwright initiated coverage of Surrozen with a rating of Buy and set a new price target of $32.00

      1/30/25 7:17:42 AM ET
      $SRZN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Surrozen upgraded by Guggenheim with a new price target

      Guggenheim upgraded Surrozen from Neutral to Buy and set a new price target of $45.00

      1/3/25 7:50:23 AM ET
      $SRZN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • B of A Securities initiated coverage on Surrozen with a new price target

      B of A Securities initiated coverage of Surrozen with a rating of Buy and set a new price target of $11.00

      10/11/21 7:02:26 AM ET
      $SRZN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $SRZN
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Large owner Column Group Iii Gp, Lp bought $11,999,991 worth of shares (1,034,482 units at $11.60) (SEC Form 4)

      4 - Surrozen, Inc./DE (0001824893) (Issuer)

      3/28/25 8:57:08 PM ET
      $SRZN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Column Group Iii Gp, Lp bought $2,999,994 worth of shares (193,548 units at $15.50) (SEC Form 4) (Amendment)

      4/A - Surrozen, Inc./DE (0001824893) (Issuer)

      4/17/24 4:14:56 PM ET
      $SRZN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Kutzkey Tim bought $2,999,994 worth of shares (193,548 units at $15.50) (SEC Form 4) (Amendment)

      4/A - Surrozen, Inc./DE (0001824893) (Issuer)

      4/17/24 4:10:51 PM ET
      $SRZN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $SRZN
    SEC Filings

    See more
    • SEC Form EFFECT filed by Surrozen Inc.

      EFFECT - Surrozen, Inc./DE (0001824893) (Filer)

      5/27/25 12:15:19 AM ET
      $SRZN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form S-3 filed by Surrozen Inc.

      S-3 - Surrozen, Inc./DE (0001824893) (Filer)

      5/20/25 4:30:56 PM ET
      $SRZN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Surrozen Inc.

      SCHEDULE 13G/A - Surrozen, Inc./DE (0001824893) (Subject)

      5/15/25 4:55:17 PM ET
      $SRZN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $SRZN
    Financials

    Live finance-specific insights

    See more
    • Surrozen Provides Fourth Quarter and Full Year 2022 Financial Results and Update on Clinical Pipeline and Corporate Progress

      Enrolled first patient in SZN-043 Ph 1a clinical trial in chronic liver disease with data expected by the end of 2023 Expect to begin SZN-043 Ph1b clinical trial in severe alcoholic hepatitis in 2024 with proof-of-concept data expected in the second half of 2024 Expect to reinitiate SZN-1326 Ph1a clinical trial in healthy volunteers by mid-2023 with data expected by the end of 2023 Anticipate potential proof-of-concept data for SZN-1326 in ulcerative colitis in the second half of 2024 Expect to nominate a fourth product candidate by the end of 2023 Corporate prioritization and restructuring result in cash runway into the second half of 2024 SOUTH SAN FRANCISCO, Calif., March 22, 2023

      3/22/23 4:01:00 PM ET
      $SRZN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Surrozen To Report Fourth Quarter and Full Year 2022 Financial Results and Provide a Corporate Update on March 22, 2023

      SOUTH SAN FRANCISCO, Calif., March 20, 2023 (GLOBE NEWSWIRE) -- Surrozen, Inc. ("Surrozen" or the "Company") (NASDAQ:SRZN), today announced that it will report fourth quarter and full year 2022 financial results and provide a corporate and pipeline progress report on Wednesday, March 22, 2023 after the close of the U.S. financial markets.   Company management will host a live audio webcast at 4:30 PM Eastern Time to discuss the corporate update and pipeline progress. Interested parties may join the audio webcast via the Investor website at www.surrozen.com. To ensure a timely connection, it is recommended that individuals register at least 15 minutes prior to the start of the webcast. Ab

      3/20/23 4:30:00 PM ET
      $SRZN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $SRZN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Exec. Vice President, Research Li Yang was granted 400 shares, increasing direct ownership by 3% to 13,043 units (SEC Form 4)

      4 - Surrozen, Inc./DE (0001824893) (Issuer)

      6/16/25 6:58:51 PM ET
      $SRZN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • CFO and COO Williams Charles O was granted 400 shares, increasing direct ownership by 4% to 9,382 units (SEC Form 4)

      4 - Surrozen, Inc./DE (0001824893) (Issuer)

      6/16/25 6:47:48 PM ET
      $SRZN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Chief Executive Officer Parker Craig C was granted 400 shares, increasing direct ownership by 6% to 7,024 units (SEC Form 4)

      4 - Surrozen, Inc./DE (0001824893) (Issuer)

      6/16/25 6:44:45 PM ET
      $SRZN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $SRZN
    Leadership Updates

    Live Leadership Updates

    See more
    • Surrozen Strengthens Board of Directors with the Appointment of Eric Bjerkholt

      SOUTH SAN FRANCISCO, Calif., April 05, 2023 (GLOBE NEWSWIRE) -- Surrozen, Inc. ("Surrozen" or the "Company") (NASDAQ:SRZN), a company pioneering targeted therapeutics that selectively activate the Wnt pathway for tissue repair and regeneration, today announced that Eric Bjerkholt has been appointed to the Board of Directors. Surrozen's Board of Directors now includes nine members with extensive experience across diverse disciplines in biotechnology and pharmaceutical development. Mr. Bjerkholt brings extensive business leadership experience across a broad range of roles and is currently CFO of Chinook Therapeutics. He most recently served as CFO of Aimmune Therapeutics, Inc. overseeing t

      4/5/23 8:30:00 AM ET
      $SRZN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Surrozen Announces Appointment of Liz Nguyen as Vice President and Head of Human Resources

      SOUTH SAN FRANCISCO, Calif., Sept. 23, 2021 (GLOBE NEWSWIRE) -- Surrozen Inc. (NASDAQ:SRZN), a biotechnology company discovering and developing drug candidates to selectively modulate the Wnt pathway, today announced that Elizabeth "Liz" Nguyen has been appointed as Vice President and Head of Human Resources (HR). Ms. Nguyen brings over 20 years of experience in organizational design, talent recruitment, building a performance culture, planning and leadership development. "Liz is joining Surrozen at a time of tremendous growth as we advance our two lead programs into the clinic and continue our momentum and progress on our broad research pipeline," said Craig Parker, President and Chief

      9/23/21 8:30:00 AM ET
      $SRZN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $SRZN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Surrozen Inc.

      SC 13G/A - Surrozen, Inc./DE (0001824893) (Subject)

      11/14/24 4:34:39 PM ET
      $SRZN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Surrozen Inc.

      SC 13G/A - Surrozen, Inc./DE (0001824893) (Subject)

      11/13/24 5:42:02 PM ET
      $SRZN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Surrozen Inc.

      SC 13G/A - Surrozen, Inc./DE (0001824893) (Subject)

      11/8/24 11:26:54 AM ET
      $SRZN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care